<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01910116</url>
  </required_header>
  <id_info>
    <org_study_id>GC6102F</org_study_id>
    <nct_id>NCT01910116</nct_id>
  </id_info>
  <brief_title>Efficacy of Shinabro in Hand Osteoarthritis</brief_title>
  <official_title>Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GCSB-5 (&quot;Shinbaro capsule&quot;), is a mixture of 6 oriental herbs that have anti-inflammatory and
      analgesic effects along with an excellent safety profile. This study is aimed at
      investigating efficacy of Shinbaro in the treatment of hand osteoarthritis which needs a long
      term treatment in a placebo controlled, double-blind randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis (OA) as a common musculoskeletal disease affects more than 30% of the elderly
      population. It frequently involves knees, hips, spines and hands. In hands, the distal and
      proximal interphalangeal and the first carpometacarpal joints are affected, leading often to
      significant disability and limitation in the daily activity. The chronic progressive nature
      of the disease requires a life-long treatment. The mainstay treatment of hand OA targets pain
      control. Non-steroidal anti-inflammatory drugs (NSAIDs) are often used. However, they are
      frequently associated with significant gastrointestinal side effects including gastritis,
      peptic ulcer diseases, and bleeding, especially with long term use. Further, they do not
      ameliorate pain completely, requiring additional medications such as acetaminophen or
      opioid-based analgesics.

      Shibaro is a mixture of purified oriental herbs consisting of Ledebouriellae Radix,
      Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, and Eucommiae
      Cortex. These herbs have been used for the treatment of diverse inflammatory conditions in
      Chines traditional medicine. All 6 herbs show an excellent safety profile and their
      anti-inflammatory and analgesic effects have been studied in both animals and humans. As
      such, given the excellent safety profile, anti-inflammatory and analgesic effects, Shinbaro
      might be ideal in the treatment of OA.

      This study will investigate the efficacy and safety of Shinbaro in the treatment of hand OA
      in a placebo-controlled, randomized, double-blind, multi-center trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUSCAN Pain Change at 4 Weeks From Baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).
AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUSCAN Pain Score at 8 Weeks From Baseline</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN Pain Score at 12 Weeks From Baseline</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN Pain Score at 16 Weeks From Baseline</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN Stiffness at 4 Weeks Change From Baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN Stiffness at 8 Weeks Change From Baseline</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN Stiffness at 12 Weeks Change From Baseline</measure>
    <time_frame>Basline and 12 weeks</time_frame>
    <description>Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN Stiffness at 16 Weeks Change From Baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN Function Change at 4 Weeks From Baseline</measure>
    <time_frame>Basline and 4 weeks</time_frame>
    <description>Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN Function Change at 8 Weeks From Baseline</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN Function Change at 12 Weeks From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN Function Change at 16 Weeks From Baseline</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment, Change From Baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment, Change From Baseline</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment, Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment, Change From Baseline</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment, Change From Baseline</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment, Change From Baseline</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment, Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment, Change From Baseline</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender Joint Count, Change From Baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender Joint Count, Change From Baseline</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender Joint Count, Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender Joint Count, Change From Baseline</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen Joint Count, Change From Baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen Joint Count, Change From Baseline</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen Joint Count, Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen Joint Count, Change From Baseline</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen Rescue</measure>
    <time_frame>Baseline 4 weeks</time_frame>
    <description>yes = AAP rescue use, no = no AAP rescue use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen Rescue</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>yes = AAP rescue use, no = no AAP rescue use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen Rescue</measure>
    <time_frame>8 weeks and 12 weeks</time_frame>
    <description>yes = AAP rescue use, no = no AAP rescue use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen Rescue</measure>
    <time_frame>12 weeks and 16 weeks</time_frame>
    <description>yes = AAP rescue use, no = no AAP rescue use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of OMERACT-OARSI Responder</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of OMERACT-OARSI Responder</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of OMERACT-OARSI Responder</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of OMERACT-OARSI Responder</measure>
    <time_frame>Baselie and 16 weeks</time_frame>
    <description>Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Hand Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 capsules, twice daily, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shinbaro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shinbaro</intervention_name>
    <description>GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem</description>
    <arm_group_label>Shinbaro</arm_group_label>
    <other_name>GCSB-5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The study medication and placebo were identical in appearance.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 40 years or older

          -  Osteoarthritis according to ACR 1990 criteria

          -  Mean joint visual analog pain score (VAS) &gt; 30mm in the preceding 48 hours

          -  Patients who are will to participate

        Exclusion Criteria:

          -  Any prior surgery of hand joints

          -  prior history of Shinbaro use

          -  Intra-articular injection of glucocorticosteroid or hyaluronic acid in the preceding 3
             months

          -  Pregnancy or active breast feeding

          -  Prior hypersensitivity reaction to herbal medications

          -  AST or ALT elevation &gt; 3 of upper normal limit

          -  GRF (MDRD) &lt; 30 mg/min/1.73m2

          -  Nephrotic syndrome, other signficant kidney disease

          -  Patients who seem not to tolerate the study at investigator's discretion

          -  Patients who refuse to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eun Bong Lee, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Kyun Park, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yun Jong Lee, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National Universty Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kichul Shin, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National Univ. Bundang Hospital</name>
      <address>
        <city>Bundang</city>
        <state>Gyeonggi-do</state>
        <zip>463-870</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Kloppenburg M. Hand osteoarthritis-nonpharmacological and pharmacological treatments. Nat Rev Rheumatol. 2014 Apr;10(4):242-51. doi: 10.1038/nrrheum.2013.214. Epub 2014 Jan 28. Review.</citation>
    <PMID>24468932</PMID>
  </reference>
  <reference>
    <citation>Shin K, Kim JW, Moon KW, Yang JA, Lee EY, Song YW, Lee EB. The efficacy of diacerein in hand osteoarthritis: a double-blind, randomized, placebo-controlled study. Clin Ther. 2013 Apr;35(4):431-9. doi: 10.1016/j.clinthera.2013.02.009. Epub 2013 Mar 6.</citation>
    <PMID>23474153</PMID>
  </reference>
  <reference>
    <citation>Kim JK, Park SW, Kang JW, Kim YJ, Lee SY, Shin J, Lee S, Lee SM. Effect of GCSB-5, a Herbal Formulation, on Monosodium Iodoacetate-Induced Osteoarthritis in Rats. Evid Based Complement Alternat Med. 2012;2012:730907. doi: 10.1155/2012/730907. Epub 2012 Mar 4.</citation>
    <PMID>22474519</PMID>
  </reference>
  <reference>
    <citation>Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage. 2004 May;12(5):389-99.</citation>
    <PMID>15094138</PMID>
  </reference>
  <reference>
    <citation>Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74. Review.</citation>
    <PMID>22563589</PMID>
  </reference>
  <reference>
    <citation>Park YG, Ha CW, Han CD, Bin SI, Kim HC, Jung YB, Lim HC. A prospective, randomized, double-blind, multicenter comparative study on the safety and efficacy of Celecoxib and GCSB-5, dried extracts of six herbs, for the treatment of osteoarthritis of knee joint. J Ethnopharmacol. 2013 Oct 7;149(3):816-24. doi: 10.1016/j.jep.2013.08.008. Epub 2013 Aug 14.</citation>
    <PMID>23954277</PMID>
  </reference>
  <reference>
    <citation>Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.</citation>
    <PMID>23726390</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2013</study_first_submitted>
  <study_first_submitted_qc>July 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <results_first_submitted>February 28, 2015</results_first_submitted>
  <results_first_submitted_qc>November 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2015</results_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Eun Bong Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>hand</keyword>
  <keyword>Shinbaro</keyword>
  <keyword>GCSB-5</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Shinbaro</title>
          <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
Shinbaro</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo 2 capsules, twice daily, for 12 weeks.
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 4</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 8</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 12</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 16</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>uncertain allocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>incomplete data</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1 patients in the Shinbaro group (n=110) and 3 in the placebo group (n=110) did not receive the allocated intervention as they withdrew immediately after randomization. Also, information on 1 patient in the placebo group was not complete leading to drop out.</population>
      <group_list>
        <group group_id="B1">
          <title>Shinbaro</title>
          <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="106"/>
            <count group_id="B3" value="215"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="7.2"/>
                    <measurement group_id="B2" value="59.4" spread="8.0"/>
                    <measurement group_id="B3" value="60.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="7.4"/>
                    <measurement group_id="B2" value="59.0" spread="8.1"/>
                    <measurement group_id="B3" value="58.9" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.7" spread="6.7"/>
                    <measurement group_id="B2" value="157.0" spread="6.0"/>
                    <measurement group_id="B3" value="156.8" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.9" spread="2.5"/>
                    <measurement group_id="B2" value="23.9" spread="2.8"/>
                    <measurement group_id="B3" value="23.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of OA</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="46.8"/>
                    <measurement group_id="B2" value="31.7" spread="47.2"/>
                    <measurement group_id="B3" value="30.1" spread="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family history of OA</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUSCAN pain (0-100)</title>
          <description>Scale ranges from 0 (no pain) to 100 (the worst possible pain).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.7" spread="16.7"/>
                    <measurement group_id="B2" value="48.2" spread="19.9"/>
                    <measurement group_id="B3" value="48.9" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUSCAN stiffness score (0-100)</title>
          <description>Scale ranges from 0 (no stiffness) to 100 (the worst possible stiffness).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="23.8"/>
                    <measurement group_id="B2" value="60.4" spread="22.8"/>
                    <measurement group_id="B3" value="57.8" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUSCAN function score (0-100)</title>
          <description>Scale ranges from 0 (no functional limitation) to 100 (the worst possible functional limitation).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="21.8"/>
                    <measurement group_id="B2" value="46.2" spread="23.9"/>
                    <measurement group_id="B3" value="46.6" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender joint count</title>
          <description>Number of tender joints on examination</description>
          <units>Joint</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="5.2"/>
                    <measurement group_id="B2" value="6.5" spread="5.2"/>
                    <measurement group_id="B3" value="7.1" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen joint count</title>
          <description>Number of swollen joints on examination (i.e. number of inflammation joints)</description>
          <units>Joint</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.6" spread="1.8"/>
                    <measurement group_id="B2" value="0.9" spread="2.4"/>
                    <measurement group_id="B3" value="0.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient global assessment (1–100)</title>
          <description>Patient’s general condition rated by patient. The Scale ranges from 0 (excellent condition) to 100 (the worst possible condition).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="16.5"/>
                    <measurement group_id="B2" value="50.1" spread="16.3"/>
                    <measurement group_id="B3" value="49.9" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician global assessment (1–100)</title>
          <description>Patient’s general condition rated by physician The Scale ranges from 0 (excellent condition) to 100 (the worst possible condition).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="11.1"/>
                    <measurement group_id="B2" value="41.5" spread="13.0"/>
                    <measurement group_id="B3" value="42.3" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte sedimentation rate (ESR)</title>
          <description>higher ESR reflects higher degree of systemic inflammation</description>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.2" spread="14.6"/>
                    <measurement group_id="B2" value="13.3" spread="10.0"/>
                    <measurement group_id="B3" value="13.8" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive protein (CRP)</title>
          <description>Higher CRP reflects higher systemic inflammation</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.09" spread="0.11"/>
                    <measurement group_id="B2" value="0.12" spread="0.26"/>
                    <measurement group_id="B3" value="0.10" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Acetaminophen</title>
          <description>Number of participants who were taking acetaminophen for pain management at baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tramadol</title>
          <description>Number of participants who were taking tramadol for pain management at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NSAIDs</title>
          <description>Number of participants who were taking NSAIDs for pain management at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucosamine</title>
          <description>Number of participants who were taking glucosamine for pain management at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diacerin</title>
          <description>Number of participants who were taking Diacerin for pain management at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Others</title>
          <description>Number of participants who were taking other OA medications for pain management at baseline.
Others .. medications for OA, not mentioned above.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUSCAN Pain Change at 4 Weeks From Baseline</title>
        <description>Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).
AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Pain Change at 4 Weeks From Baseline</title>
          <description>Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).
AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" lower_limit="-23.6" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="-2.2" lower_limit="-16.6" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming that an improvement in AUSCAN pain score of &gt;10 is clinically meaningful, and assuming an alpha level of 0.05 (two-tailed), a power of 0.80, and a dropout rate of 20%, the sample size calculation revealed that 220 patients should be enrolled.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUSCAN Pain Score at 8 Weeks From Baseline</title>
        <description>Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Pain Score at 8 Weeks From Baseline</title>
          <description>Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" lower_limit="-26.2" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-2.2" lower_limit="-17.4" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUSCAN Pain Score at 12 Weeks From Baseline</title>
        <description>Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Pain Score at 12 Weeks From Baseline</title>
          <description>Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.6" lower_limit="-30.4" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-8.0" lower_limit="-25.0" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUSCAN Pain Score at 16 Weeks From Baseline</title>
        <description>Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Pain Score at 16 Weeks From Baseline</title>
          <description>Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" lower_limit="-28.2" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-4.4" lower_limit="-24.8" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUSCAN Stiffness at 4 Weeks Change From Baseline</title>
        <description>Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Stiffness at 4 Weeks Change From Baseline</title>
          <description>Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" lower_limit="-22.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="-6.0" lower_limit="-23.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.728</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUSCAN Stiffness at 8 Weeks Change From Baseline</title>
        <description>Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Stiffness at 8 Weeks Change From Baseline</title>
          <description>Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.0" lower_limit="-28" upper_limit="2"/>
                    <measurement group_id="O2" value="-6" lower_limit="-27" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.229</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUSCAN Stiffness at 12 Weeks Change From Baseline</title>
        <description>Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Basline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Stiffness at 12 Weeks Change From Baseline</title>
          <description>Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" lower_limit="-36.0" upper_limit="0"/>
                    <measurement group_id="O2" value="-11.0" lower_limit="-29.8" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.194</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUSCAN Stiffness at 16 Weeks Change From Baseline</title>
        <description>Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Stiffness at 16 Weeks Change From Baseline</title>
          <description>Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" lower_limit="-27.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-8.0" lower_limit="-27" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.347</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUSCAN Function Change at 4 Weeks From Baseline</title>
        <description>Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Basline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Function Change at 4 Weeks From Baseline</title>
          <description>Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" lower_limit="-18.9" upper_limit="3.6"/>
                    <measurement group_id="O2" value="-3.7" lower_limit="-13.7" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.122</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUSCAN Function Change at 8 Weeks From Baseline</title>
        <description>Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Function Change at 8 Weeks From Baseline</title>
          <description>Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" lower_limit="-26.9" upper_limit="2.6"/>
                    <measurement group_id="O2" value="-4.8" lower_limit="-18.6" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.097</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUSCAN Function Change at 12 Weeks From Baseline</title>
        <description>Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Function Change at 12 Weeks From Baseline</title>
          <description>Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" lower_limit="-27.8" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-18.7" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUSCAN Function Change at 16 Weeks From Baseline</title>
        <description>Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUSCAN Function Change at 16 Weeks From Baseline</title>
          <description>Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" lower_limit="-28.7" upper_limit="1.8"/>
                    <measurement group_id="O2" value="-4.8" lower_limit="-18.7" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment, Change From Baseline</title>
        <description>Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment, Change From Baseline</title>
          <description>Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" lower_limit="-24.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-15.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment, Change From Baseline</title>
        <description>Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment, Change From Baseline</title>
          <description>Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" lower_limit="-24.5" upper_limit="0"/>
                    <measurement group_id="O2" value="-6.0" lower_limit="-18.0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment, Change From Baseline</title>
        <description>Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment, Change From Baseline</title>
          <description>Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" lower_limit="-30.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-6.0" lower_limit="-24.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment, Change From Baseline</title>
        <description>Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment, Change From Baseline</title>
          <description>Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" lower_limit="-29.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="-8.5" lower_limit="-21.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.221</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment, Change From Baseline</title>
        <description>Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment, Change From Baseline</title>
          <description>Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" lower_limit="-21.0" upper_limit="0"/>
                    <measurement group_id="O2" value="-7.0" lower_limit="-19.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.174</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment, Change From Baseline</title>
        <description>Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment, Change From Baseline</title>
          <description>Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" lower_limit="-26.0" upper_limit="-4.0"/>
                    <measurement group_id="O2" value="-11.5" lower_limit="-25.3" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.124</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment, Change From Baseline</title>
        <description>Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment, Change From Baseline</title>
          <description>Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.0" lower_limit="-29.0" upper_limit="-5.0"/>
                    <measurement group_id="O2" value="-13" lower_limit="-27.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment, Change From Baseline</title>
        <description>Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment, Change From Baseline</title>
          <description>Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" lower_limit="-23.5" upper_limit="0"/>
                    <measurement group_id="O2" value="-6.5" lower_limit="-20.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.126</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tender Joint Count, Change From Baseline</title>
        <description>Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tender Joint Count, Change From Baseline</title>
          <description>Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>joints</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-4" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-3.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tender Joint Count, Change From Baseline</title>
        <description>Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tender Joint Count, Change From Baseline</title>
          <description>Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>Joints</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-4.0" upper_limit="0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.660</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tender Joint Count, Change From Baseline</title>
        <description>Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tender Joint Count, Change From Baseline</title>
          <description>Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>joints</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-5.0" upper_limit="0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-4.0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tender Joint Count, Change From Baseline</title>
        <description>Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tender Joint Count, Change From Baseline</title>
          <description>Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>joints</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-5.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-5.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.186</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swollen Joint Count, Change From Baseline</title>
        <description>Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Swollen Joint Count, Change From Baseline</title>
          <description>Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>Joints</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.493</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swollen Joint Count, Change From Baseline</title>
        <description>Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Swollen Joint Count, Change From Baseline</title>
          <description>Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>Joints</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swollen Joint Count, Change From Baseline</title>
        <description>Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Swollen Joint Count, Change From Baseline</title>
          <description>Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>Joints</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.604</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swollen Joint Count, Change From Baseline</title>
        <description>Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Swollen Joint Count, Change From Baseline</title>
          <description>Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
          <units>Joints</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.252</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acetaminophen Rescue</title>
        <description>yes = AAP rescue use, no = no AAP rescue use</description>
        <time_frame>Baseline 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Acetaminophen Rescue</title>
          <description>yes = AAP rescue use, no = no AAP rescue use</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.378</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acetaminophen Rescue</title>
        <description>yes = AAP rescue use, no = no AAP rescue use</description>
        <time_frame>4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Acetaminophen Rescue</title>
          <description>yes = AAP rescue use, no = no AAP rescue use</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.485</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acetaminophen Rescue</title>
        <description>yes = AAP rescue use, no = no AAP rescue use</description>
        <time_frame>8 weeks and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Acetaminophen Rescue</title>
          <description>yes = AAP rescue use, no = no AAP rescue use</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acetaminophen Rescue</title>
        <description>yes = AAP rescue use, no = no AAP rescue use</description>
        <time_frame>12 weeks and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Acetaminophen Rescue</title>
          <description>yes = AAP rescue use, no = no AAP rescue use</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.683</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of OMERACT-OARSI Responder</title>
        <description>Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of OMERACT-OARSI Responder</title>
          <description>Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonresponder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of OMERACT-OARSI Responder</title>
        <description>Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of OMERACT-OARSI Responder</title>
          <description>Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nonresponder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of OMERACT-OARSI Responder</title>
        <description>Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of OMERACT-OARSI Responder</title>
          <description>Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nonresponder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of OMERACT-OARSI Responder</title>
        <description>Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
        <time_frame>Baselie and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Shinbaro</title>
            <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of OMERACT-OARSI Responder</title>
          <description>Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Any event between randomization (week 0) and study end (week 16)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Shinbaro</title>
          <description>GCSB-5 (Shinbaro), 2 capsules (300mg), twice daily, for 12 weeks
observation for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo 2 capsules, twice daily, for 12 weeks.
observation for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Surgery</sub_title>
                <description>Surgery</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>liver function abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Fracture</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual floater</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver function change</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressive mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Eun Bong Lee</name_or_title>
      <organization>Seoul National University Hospital</organization>
      <phone>822-2072-3944</phone>
      <email>leb7616@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

